Imat 400 MG Tablet contains Imatinib Mesylate 400mg, a standard-dose BCR-ABL TKI offering the same targeted cancer therapy as Imatib and Veenat in a high-quality generic formulation for CML and GIST.

How It Works: Imatinib selectively inhibits BCR-ABL, KIT, and PDGFR kinase enzymes, disrupting oncogenic signaling pathways and blocking the proliferation of leukemia and GIST tumor cells.

Common Uses: Chronic myeloid leukemia, GIST, Ph+ ALL, and other BCR-ABL or KIT-driven malignancies where imatinib-based targeted therapy is indicated.

Administration: Take once daily (or split doses) with a meal and ample water. Consistent daily dosing maintains therapeutic drug levels. Follow oncologist-prescribed schedule.

Storage: Store below 30°C away from moisture. Keep in original packaging out of children's reach.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.